Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy is a research paper published in Journal of Thoracic Oncology (2021). On theSindex it has a DataRank of 0.731. It has been cited 130 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.731
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: P30 CA124435
Eli Lilly and Company
EpicentRx
National Cancer Institute
Spectrum Pharmaceuticals
Jounce Therapeutics
Novartis
Bayer Fund
Celgene
Medtronic
Merck
National Institutes of Health
Revolution Medicines
ACEA Biosciences
AstraZeneca
Bristol-Myers Squibb
Calithera Biosciences
Daiichi-Sankyo
GlaxoSmithKline
Pfizer
Roche
Amgen
Boehringer Ingelheim
Takeda Pharmaceuticals U.S.A.
FWCI
8.69
Citation Percentile
1.0%
Influential Citations
7
Citation Trend
Fields of Study
MeSH Terms
Keywords
Additional file 1 of Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment
Additional file 1 of Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment
Additional file 2 of Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment
Additional file 2 of Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment